Renaissance Technologies’s MoonLake Immunotherapeutics MLTX Stock Holding History

Renaissance Technologies’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.16M	Buy	276,772 +142,300	+106%	+$2.36M	0.01%	1365
2025 Q4	$1.77M	Buy	+134,472	New	+$1.59M	﹤0.01%	1938
2023 Q4	–	Sell	-13,396	Closed	-$764K	–	3976
2023 Q3	$764K	Sell	13,396 -2,104	-14%	-$116K	﹤0.01%	2477
2023 Q2	$791K	Sell	15,500 -7,200	-32%	-$194K	﹤0.01%	2611
2023 Q1	$486K	Buy	22,700 +11,091	+96%	+$186K	﹤0.01%	2905
2022 Q4	$122K	Buy	+11,609	New	+$103K	﹤0.01%	3561

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies's MLTX Position: Q1 2026 in Review

Renaissance Technologies increased its MoonLake Immunotherapeutics (MLTX) stake by 106% in Q1 2026, buying an estimated $2.36M and bringing the position to 276,772 shares worth $5.16M. The position accounts for 0.01% of the portfolio, ranked #1365.

Renaissance Technologies first reported a position in MLTX in Q4 2022 and has held it in 6 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Renaissance Technologies held 276,772 shares of MoonLake Immunotherapeutics worth $5.16M as of Q1 2026.
Renaissance Technologies bought 142,300 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.36M.
MoonLake Immunotherapeutics made up 0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1365 holding.
Renaissance Technologies first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 6 quarters since.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.